A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease

Trial Profile

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs GBT 440 (Primary)
  • Indications Sickle cell anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms GBT-HOPE; HOPE
  • Sponsors Global Blood Therapeutics
  • Most Recent Events

    • 24 Jan 2017 According to a Global Blood Therapeutics media release, first patient is enrolled in this study.
    • 05 Dec 2016 According to a Global Blood Therapeutics media release, Patient Reported Outcome (PRO) instrument development was undertaken in collaboration with sickle cell disease patient groups and external experts, and with active engagement with the Clinical Outcomes Assessment group of the U. S. FDA.
    • 04 Dec 2016 Status changed from not yet recruiting to recruiting, as reported in a Global Blood Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top